Dimethyl Fumarate, Temozolomide, and Radiation Therapy in Treating Patients With Newly Diagnosed Glioblastoma Multiforme

Inclusion Criteria: * Histopathologically proven diagnosis of glioblastoma or gliosarcoma (World Health Organization \[WHO\] grade IV) following either a surgical resection or biopsy * Eastern Cooperative Oncology Group (ECOG) performance status 0-2 * Subjects must have recovered from surgery or biopsy before study registration * Therapy must begin between 21 days (3 weeks) and 42 days (6 weeks) after the most recent brain tumor surgery(resection or biopsy) * Documentation of steroid doses 10-14 days prior to study registration and stable or decreasing steroid dose over the week prior to registration * Absolute neutrophil count (ANC) \>= 1500/mm\^3 * Platelets \>= 100,000/mm\^3 (untransfused) * Hemoglobin \>= 10 g/dL (the use of transfusion or other intervention to achieve hemoglobin \>= 10 g/dL is acceptable) * Creatinine =\< 1.5 x upper limit of normal (ULN) for the laboratory or calculated or actual creatinine clearance \> 45 mL/min * Total bilirubin =\< 1.5 x ULN for the laboratory (total bilirubin criteria may be waived if a subject has documented Gilbert's syndrome) * Aspartate aminotransferase (AST) =\< 3 x ULN for the laboratory * Alanine aminotransferase (ALT) =\< 3 x ULN for the laboratory * Women of childbearing potential and male subjects must practice adequate contraception * Ability to understand and the willingness to sign a written informed consent document Exclusion Criteria: * Prior invasive malignancy (except for non-melanoma skin cancer) unless disease free for \>= 3 years * Recurrent malignant gliomas * Metastases detected below the tentorium or beyond the cranial vault * Prior chemotherapy or radiation therapy (RT) for the diagnosis of GBM or for cancers of the head and neck * Clinically significant cardiac disease, including major cardiac dysfunction, such as uncontrolled angina, clinical congestive heart failure with New York Heart Association (NYHA) class III or IV, ventricular arrhythmias requiring anti-arrhythmic therapy * Pregnant or lactating women * History of allergic reactions or intolerance to any of the required agents on the study * History of hypersensitivity to dacarbazine * Any treatment for GBM, other than surgery or anti-epileptic therapy, within 30 days prior to study treatment initiation * Other condition(s) that in the opinion of the investigator might compromise the objectives of the study or increase patient risk